SELENBP1 and acute kidney injury: The elevated serum concentrations of SELENBP1 were significantly associated with adverse outcomes, and predictive to discriminate patients at risk from those with negligible risk for death, bradycardia, cerebral ischemia, stay at the ICU for > 40 days, acute kidney injury or pneumonia (Table 2).